Room 810, 8F, No. 780, Cailun Road, Pudong New Area, Shanghai, China.
About us
Puheng Biomedicine (Shanghai) Co., Ltd.
Puheng Biomedicine (Shanghai) Co., Ltd is an innovative enterprise focused on the research and development and application of novel in vitro 3D organ/disease models, including complex 3D models such as NAC-Organ, organoids, organ-on-a-chip, etc. The company's independently developed NAC-Organ technology is the world's first assembly-based in vitro 3D model construction and culture technique based on nano-nucleic acid materials, capable of rapidly achieving high-throughput, standardized production of humanized complex organ/disease models. The company has established modeling techniques for common chronic diseases with chronic liver disease as a characteristic, various tumors, important physiological organs...
-
Development of in vitro 3D complex disease models
-
Drug screening based on in vitro 3D models
-
Development of Regenerative medicine technology
PUHENG has accumulated thousands of experimental data to provide you with reliable products and services.
MORE
Leading technological innovation and industrial transformation
-
NAC-linker is a Cell junction material developed by PUHENG Technology based on Synthetic biology technology.It enables efficient self-assembly of cells in a three-dimensional space and allows precise control over cell types, quantities, and spatial distri
-
Our NAC-Organ technology allows for the preparation of a 3D liver model (NAC-Liver) containing hepatocytes and non-parenchymal cells within 24 hours. NAC-Liver can be stably cultured in vitro for over 30 days, maintaining high levels of hepatocyte secreti
-
The automated cultivation system developed for NAC-organ enables high-throughput automated cultivation and testing of 3D models, ensuring standardization of the models and reproducibility of the test results. By utilizing high-content imaging systems, hig
Industry News
News Center
喜讯！《Science Advances》刊登：3D培养技术新突破，朴衡NAC-Organ技术引领药物筛选新时代
传统的细胞培养和动物模型在预测人体药物反应、探索致病机制上有其固有局限性，新兴的体外3D培养技术有望在多个方面突破传统方法的限制。随着外模型的仿真性、生理相关性的不断突破，培养系统也变得越来越复杂，这阻碍了其在自动化、高通量药物筛选流程上的整合。传统的细胞球体模型虽适合高通量筛选，但无法复现组织器官的复杂结构，从而限制了对复杂疾病的精确建模。因此，开发能在模型复杂性和可操作性之间取得平衡的新型仿生组织工程策略成为推动技术实用化的关键挑战。
文献解读 | 探索肿瘤微环境的奥秘：3D类器官模型引领肿瘤研究新纪元
当代肿瘤治疗研究的一个关键领域是深入理解肿瘤免疫微环境（TME）的复杂性，并探索如何利用这一环境来开发更有效的免疫治疗策略。近日，斯坦福大学Calvin J. Kuo教授在《Nature reviews cancer》（IF = 72.5）发表综述“Cancer organoids 2.0: modelling the complexity of the tumor immune microenvironment”。本文主要综述了肿瘤类器官在模拟肿瘤免疫微环境的复杂性的方法，以及如何能够通过这种复杂模型精
朴衡博迈完成新一轮融资
朴衡博迈（上海）生物医药有限公司（以下简称“朴衡博迈”，原苏州朴衡科技有限公司）近日完成新一轮融资。本轮由浦东创投旗下浦东科技投资天使母基金独家投资，至此朴衡博迈累计融资数千万元。募集资金主要用于NAC-organ技术和体外药物研发平台的持续开发与商业转化。
看得见的浸润 | 朴衡科技助力鲲石生物发布CAR-M体外3D评估模型成果
近日，『朴衡科技』与『鲲石生物』的战略合作成果在生命科学预印本平台“bioRxiv”上发表：https://www.biorxiv.org/content/10.1101/2023.12.03.569750v1
